by Mariam Kiparoidze | Sep 28, 2023
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.69 per share, down by 36.2% year to date on September 22. Moderna (Nasdaq:MRNA) ended the week on a...
by Suzannah Cavanaugh | Dec 16, 2020
This time last year, Moderna, Inc., was starting to look a lot like Theranos. Moderna had spent the large part of a decade selling investors on the idea of an unprecedented product—a messenger RNA drug. The company, valued at $7.5 billion, made history in December...
by Suzannah Cavanaugh | Oct 30, 2020
In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates. The company touted 37% enrollment by people of color in late-stage trials, a figure that nearly mirrors the 40% of the population U.S....
by Suzannah Cavanaugh | Oct 2, 2020
Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...
